Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

S Opat; A Tedeschi; B Hu; KM Linton; P McKay; H Chan; J Jin; MY Sun; M Sobieraj-Teague; PL Zinzani; PJ Browett; XY Ke; CA Portell; C Thieblemont; K Ardeshna; F Bijou; P Walker; E Hawkes; SJ Ho; KS Zhou; ZY Liang; JF Xu; C Tankersley; R Delarue; M Co; J Trotman

doi:10.1182/blood-2022-163371

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

S Opat, A Tedeschi, B Hu, KM Linton, P McKay, H Chan, J Jin, MY Sun, M Sobieraj-Teague, PL Zinzani, PJ Browett, XY Ke, CA Portell, C Thieblemont, K Ardeshna, F Bijou, P Walker, E Hawkes, SJ Ho, KS ZhouZY Liang, JF Xu, C Tankersley, R Delarue, M Co, J Trotman

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	4
Journal	Blood
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-163371
Publication status	Published - 15 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2022-163371

Cite this

Opat, S., Tedeschi, A., Hu, B., Linton, KM., McKay, P., Chan, H., Jin, J., Sun, MY., Sobieraj-Teague, M., Zinzani, PL., Browett, PJ., Ke, XY., Portell, CA., Thieblemont, C., Ardeshna, K., Bijou, F., Walker, P., Hawkes, E., Ho, SJ., ... Trotman, J. (2022). Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial. Blood, 140. https://doi.org/10.1182/blood-2022-163371

@article{b5d248a49c4e4a2189bdb5d86819dd82,

title = "Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial",

author = "S Opat and A Tedeschi and B Hu and KM Linton and P McKay and H Chan and J Jin and MY Sun and M Sobieraj-Teague and PL Zinzani and PJ Browett and XY Ke and CA Portell and C Thieblemont and K Ardeshna and F Bijou and P Walker and E Hawkes and SJ Ho and KS Zhou and ZY Liang and JF Xu and C Tankersley and R Delarue and M Co and J Trotman",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-163371",

language = "English",

volume = "140",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

Opat, S, Tedeschi, A, Hu, B, Linton, KM, McKay, P, Chan, H, Jin, J, Sun, MY, Sobieraj-Teague, M, Zinzani, PL, Browett, PJ, Ke, XY, Portell, CA, Thieblemont, C, Ardeshna, K, Bijou, F, Walker, P, Hawkes, E, Ho, SJ, Zhou, KS, Liang, ZY, Xu, JF, Tankersley, C, Delarue, R, Co, M & Trotman, J 2022, 'Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial', Blood, vol. 140. https://doi.org/10.1182/blood-2022-163371

TY - JOUR

T1 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL)

T2 - Final Analysis of the Magnolia (BGB-3111-214) Trial

AU - Opat, S

AU - Tedeschi, A

AU - Hu, B

AU - Linton, KM

AU - McKay, P

AU - Chan, H

AU - Jin, J

AU - Sun, MY

AU - Sobieraj-Teague, M

AU - Zinzani, PL

AU - Browett, PJ

AU - Ke, XY

AU - Portell, CA

AU - Thieblemont, C

AU - Ardeshna, K

AU - Bijou, F

AU - Walker, P

AU - Hawkes, E

AU - Ho, SJ

AU - Zhou, KS

AU - Liang, ZY

AU - Xu, JF

AU - Tankersley, C

AU - Delarue, R

AU - Co, M

AU - Trotman, J

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000893223200234&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2022-163371

DO - 10.1182/blood-2022-163371

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

JO - Blood

JF - Blood

ER -

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

UN SDGs

Access to Document

Other files and links

Cite this